These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 30786068)

  • 1. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients.
    Mak LY; Ko M; To E; Wong DK; Ma JH; Hui TL; Seto WK; Fung J; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1817-1823. PubMed ID: 30786068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.
    Mak LY; To WP; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
    World J Gastroenterol; 2019 Mar; 25(11):1398-1408. PubMed ID: 30918432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B.
    Hsu YC; Jun T; Huang YT; Yeh ML; Lee CL; Ogawa S; Cho SH; Lin JT; Yu ML; Nguyen MH; Tanaka Y
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1128-1137. PubMed ID: 30306612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
    Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
    J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis.
    Su TH; Peng CY; Tseng TC; Yang HC; Liu CJ; Liu CH; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2020 Feb; 221(4):589-597. PubMed ID: 31574141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy.
    Murata A; Amano N; Sato S; Tsuzura H; Tomishima K; Sato S; Matsumoto K; Shimada Y; Iijima K; Genda T
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
    Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
    J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma.
    Mak LY; Ko KL; To WP; Wong DK; Seto WK; Fung J; Yuen MF
    Gut Liver; 2020 Sep; 14(5):665-668. PubMed ID: 32457279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection.
    Mak LY; Wong DK; Seto WK; Ning Q; Cheung KS; Fung J; Lai CL; Yuen MF
    Hepatol Int; 2019 Mar; 13(2):148-156. PubMed ID: 30671807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.
    Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Yakushijin T; Iio S; Doi Y; Yamada A; Kaneko A; Hagiwara H; Mita E; Oshita M; Itoh T; Fukui H; Hijioka T; Katayama K; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
    J Gastroenterol; 2015 Jul; 50(7):785-94. PubMed ID: 25384794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients.
    Liu J; Hu HH; Lee MH; Korenaga M; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; Mizokami M; Chen CJ; Yang HI
    Sci Rep; 2017 Oct; 7(1):14352. PubMed ID: 29085039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
    Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
    BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
    Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
    J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
    Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
    Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection.
    Mak LY; Wong DK; Cheung KS; Seto WK; Lai CL; Yuen MF
    Clin Transl Gastroenterol; 2018 Jun; 9(6):163. PubMed ID: 29915243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
    Nagata H; Nakagawa M; Nishimura-Sakurai Y; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Goto F; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Tojo N; Tohda S; Asahina Y; Watanabe M;
    Hepatol Int; 2016 Nov; 10(6):956-964. PubMed ID: 27435935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Shin JW; Jeong J; Jung SW; Lee SB; Park BR; Kim MJ; Park EJ; Park NH
    Dig Dis Sci; 2021 May; 66(5):1739-1750. PubMed ID: 32524416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
    Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
    Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir.
    Chiang HH; Lee CM; Hu TH; Hung CH; Wang JH; Lu SN; Lai HC; Su WP; Lin CH; Peng CY; Chen CH
    Liver Int; 2018 Nov; 38(11):1997-2005. PubMed ID: 29797410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.